{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:59:41Z","timestamp":1781161181371,"version":"3.54.1"},"reference-count":25,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: AF in the setting of cardiac amyloidosis is associated with a high risk of TEs, irrespective of CHA2DS2-VASc score. While warfarin has been the traditional anticoagulant, DOACs offer a promising alternative, but their safety in this population remains underexplored. This study aimed to evaluate the prevalence of thromboembolic events (TEs), including stroke and transient ischemic attack (TIA), and major bleeding events in patients with cardiac amyloidosis (CA) and atrial fibrillation (AF) treated with either warfarin or direct oral anticoagulants (DOACs). Additionally, we aimed to explore whether DOACs are at least as effective as warfarin in protecting against TEs in this population. Methods: This retrospective cohort study analyzed 422 patients with confirmed CA and AF from Mayo Clinic, with a median follow-up of 4.3 years. Data on anticoagulation therapy, baseline characteristics, and outcomes (TEs and bleeding) were collected. Statistical analyses included chi-square tests, t-tests, and Cox regression to assess the relationship between anticoagulation and TE. Results: Among 422 patients, 21 experienced a TE. The annual event rate was 0.83% for warfarin and 0.67% for DOACs, with no significant difference (HR 0.66, CI 0.22\u20132.01, p = 0.5). Patients with anticoagulation interruptions &gt; 5 days had increased TE risk (HR 3.19, CI 0.97\u201310.5, p = 0.056). The bleeding rate was 9.9% over 4.3 years (2.33% per year), with no significant differences between anticoagulants. Conclusions: Both warfarin and DOACs have similar, low risks of TEs in CA and AF patients. However, anticoagulation interruptions were associated with increased TE risk, emphasizing the challenges in managing anticoagulation in this population.<\/jats:p>","DOI":"10.3390\/jcdd13060259","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0940-0168","authenticated-orcid":false,"given":"Hussein","family":"Abdul Nabi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-9292","authenticated-orcid":false,"given":"Luke","family":"Dreher","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3184-5116","authenticated-orcid":false,"given":"Michael","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Al Osta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-3710","authenticated-orcid":false,"given":"Suganya A.","family":"Karikalan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiad","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-2862","authenticated-orcid":false,"given":"Hicham Z.","family":"El Masry","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, Mayo Clinic Hospital, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.cpcardiol.2022.101571","article-title":"Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis","volume":"48","author":"Bukhari","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e006619","DOI":"10.1161\/CIRCHEARTFAILURE.119.006619","article-title":"Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis","volume":"13","author":"Cappelli","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: Clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Teresi, L., Trimarchi, G., Liotta, P., Restelli, D., Licordari, R., Carciotto, G., Francesco, C., Crea, P., Dattilo, G., and Micari, A. (2024). Electrocardiographic Patterns and Arrhythmias in Cardiac Amyloidosis: From Diagnosis to Therapeutic Management-A Narrative Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185588"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: A review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_7","first-page":"494","article-title":"New challenges in the management of patients with transthyretin cardiac amyloidosis: Beyond oral anticoagulation","volume":"76","year":"2023","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cardfail.2022.08.008","article-title":"Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: A review","volume":"29","author":"Bukhari","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Monte, I.P., Faro, D.C., Trimarchi, G., de Gaetano, F., Campisi, M., Losi, V., Teresi, L., Di Bella, G., Tamburino, C., and de Gregorio, C. (2023). Left Atrial Strain Imaging by Speckle Tracking Echocardiography: The Supportive Diagnostic Value in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10060261"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Writing Committee, Kittleson, M.M., Ruberg, F.L., Ambardekar, A.V., Brannagan, T.H., Cheng, R.K., Clarke, J.O., Dember, L.M., Frantz, J.G., and Hershberger, R.E. (2023). 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol., 81, 1076\u20131126. Erratum in J. Am. Coll. Cardiol. 2023, 81, 1135. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.013.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"Dispenzieri","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: Comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.amjcard.2021.10.018","article-title":"Direct oral anticoagulants in cardiac amyloidosis-associated heart failure and atrial fibrillation","volume":"164","author":"Mentias","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding manifestations in 100 patients with amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Fotiou, D., Gavriatopoulou, M., and Terpos, E. (2020). Multiple myeloma and thrombosis: Prophylaxis and risk prediction tools. Cancers, 12.","DOI":"10.3390\/cancers12010191"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.jtha.2024.05.018","article-title":"Thromboembolic and bleeding risk in cardiac amyloidosis","volume":"22","author":"Tana","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","first-page":"503","article-title":"Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study","volume":"76","author":"Mohandes","year":"2023","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.hrthm.2022.03.1146","article-title":"Ischemic stroke after prophylaxis with left atrial appendage closure vs. non-warfarin oral anticoagulants: A \u201creal-world\u201d multicenter comparison of stroke severity","volume":"19","author":"Turagam","year":"2022","journal-title":"Heart Rhythm."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/6\/259\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:36:16Z","timestamp":1781159776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/6\/259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcdd13060259"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13060259","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}